Details for Patent: 5,856,529

Which drugs does patent 5,856,529 protect, and when does it expire?

Patent 5,856,529 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.

This patent has thirty-one patent family members in twenty-four countries.

Summary for Patent: 5,856,529

Title:	Benzofuran and dihydrobenzofuran melatonergic agents
Abstract:	Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.
Inventor(s):	Catt; John D. (Southington, CT), Johnson; Graham (Madison, CT), Keavy; Daniel J. (Killingworth, CT), Mattson; Ronald J. (Meriden, CT), Parker; Michael F. (Middletown, CT), Takaki; Katherine S. (Middletown, CT), Yevich; Joseph P. (Southington, CT)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	08/987,478
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent 5,856,529

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014		RX	Yes	Yes			Y	Y		TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014		RX	Yes	Yes			Y	Y		TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes			Y	Y		TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON

International Family Members for US Patent 5,856,529

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	010346
Austria	281833
Australia	5598598
Australia	719994
Brazil	9713690
Canada	2274183